logo
  • Über uns
    • Über uns
    • Führungsteam
    • Unsere Verantwortung
    • Kollaborationen
    • Unsere Standorte
  • Technologie
    • Technologie
    • Produktion
    • Publikationen
  • Pipeline
  • Newsroom
    • News
    • Events
    • Downloads
  • Investor Relations
    • Überblick
    • Analysten-Coverage
    • Hauptversammlung
    • Finanzberichte
    • Corporate Governance
    • E-Mail Alert
  • Karriere
    • Werden Sie Teil der RNA people
    • Ausbildung
    • Aktuelle Stellenangebote
  • DE

Mechanism of Action

mRNA-Based Vaccines and Mode of Action


by Barbara Koegel-Hubbuch

Unifying in vitro and in vivo IVT mRNA expression discrepancies in skeletal muscle via mechanotransduction


by Sovereign

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines


by Sovereign

mRNA mediates passive vaccination against infectious agents, toxins, and tumors


by Sovereign

A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects


by Sovereign

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response


by Sovereign

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity


by Sovereign

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs


by Sovereign

Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals


by Sovereign

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors


by Sovereign

  • 1
  • 2
  • 3